CA2795520C - Methods and compositions for treating wounds utilizing chitosan compounds - Google Patents

Methods and compositions for treating wounds utilizing chitosan compounds Download PDF

Info

Publication number
CA2795520C
CA2795520C CA2795520A CA2795520A CA2795520C CA 2795520 C CA2795520 C CA 2795520C CA 2795520 A CA2795520 A CA 2795520A CA 2795520 A CA2795520 A CA 2795520A CA 2795520 C CA2795520 C CA 2795520C
Authority
CA
Canada
Prior art keywords
wound
alkyl substituted
group
chitosan
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2795520A
Other languages
English (en)
French (fr)
Other versions
CA2795520A1 (en
Inventor
Shenda Baker
Ruth Baxter
William P. Wiesmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synedgen Inc
Original Assignee
Synedgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synedgen Inc filed Critical Synedgen Inc
Publication of CA2795520A1 publication Critical patent/CA2795520A1/en
Application granted granted Critical
Publication of CA2795520C publication Critical patent/CA2795520C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
CA2795520A 2010-04-06 2011-04-06 Methods and compositions for treating wounds utilizing chitosan compounds Active CA2795520C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32143710P 2010-04-06 2010-04-06
US61/321,437 2010-04-06
US201161451430P 2011-03-10 2011-03-10
US61/451,430 2011-03-10
PCT/US2011/031385 WO2011127144A1 (en) 2010-04-06 2011-04-06 Methods and compositions for treating wounds utilizing chitosan compounds

Publications (2)

Publication Number Publication Date
CA2795520A1 CA2795520A1 (en) 2011-10-13
CA2795520C true CA2795520C (en) 2018-03-06

Family

ID=44763261

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2795520A Active CA2795520C (en) 2010-04-06 2011-04-06 Methods and compositions for treating wounds utilizing chitosan compounds

Country Status (7)

Country Link
US (5) US9439925B2 (enExample)
EP (1) EP2555760B1 (enExample)
JP (4) JP2013523827A (enExample)
AU (1) AU2011237682B2 (enExample)
CA (1) CA2795520C (enExample)
ES (1) ES2773017T3 (enExample)
WO (1) WO2011127144A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848648C (en) 2006-06-02 2017-10-10 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
CA3004707C (en) 2009-09-02 2022-05-31 Synedgen Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
ES2773017T3 (es) 2010-04-06 2020-07-09 Synedgen Inc Derivados de quitosano para el tratamiento de mucositis o ulceración
US20150031610A1 (en) * 2012-03-05 2015-01-29 Synedgen, Inc. Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins
CN102755662B (zh) * 2012-07-25 2014-01-08 福州乾正药业有限公司 一种复合壳聚糖凝胶膜及其制备方法
US10022393B2 (en) * 2012-09-20 2018-07-17 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation, trauma or shock
TWI478943B (zh) * 2012-12-27 2015-04-01 Ind Tech Res Inst 高分子組成物用於製備具有抑制基質金屬蛋白酶之活性的功效的醫療器材或抑制劑的用途
CN103893813B (zh) * 2012-12-28 2018-04-17 财团法人工业技术研究院 高分子组合物与高分子材料
CA2905404C (en) 2013-03-12 2021-07-20 Synedgen, Inc. Oral formulations of polyglucosamine derivatives in combination with a non-fermentable sugar
WO2014172040A1 (en) * 2013-03-15 2014-10-23 Synedgen Inc. Compositions and methods of use for wound healing
WO2015022907A1 (ja) * 2013-08-13 2015-02-19 生化学工業株式会社 カチオン化キトサンを含有する医薬
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
AU2015314775A1 (en) 2014-09-11 2017-03-30 Synedgen, Inc. Compositions and methods of use thereof
CN108348455B (zh) * 2015-10-30 2021-04-09 克罗马药品股份有限公司 无菌水性眼用溶液的治疗用途
PL3368006T3 (pl) * 2015-10-30 2020-06-01 Croma-Pharma Gesellschaft M.B.H. Zastosowanie terapeutyczne sterylnego wodnego roztworu oftalmicznego
EP3429602B1 (en) * 2016-03-16 2025-05-07 Synedgen, Inc. Compositions comprising a polyglucosamine-arginine and their use to treat dysbiosis
CN108096182A (zh) * 2016-11-25 2018-06-01 哈尔滨盈聚生物科技有限公司 一种基于绿色抗菌材料的妇科抗菌凝胶及其制备方法
US10918699B2 (en) * 2017-03-22 2021-02-16 Michael C. Struck Therapeutic treatment for neurotrophic keratopathy
WO2018202783A1 (en) 2017-05-03 2018-11-08 Croma-Pharma Gmbh Sterile aqueous ophthalmic solution containing n-(n-acetylcysteinyl)-chitosan for treating non-infectious corneal disorders
TWI633888B (zh) * 2017-10-03 2018-09-01 黃琮瑋 醣類物質用於製備改善嗅覺功能的藥物之用途
CN107970269A (zh) * 2017-12-30 2018-05-01 广州润虹医药科技股份有限公司 一种含有壳聚糖的口腔溃疡膜及其制备方法
RU2697869C1 (ru) * 2018-04-28 2019-08-21 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Фармацевтическая субстанция для лечения инфицированных ран различного генеза
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
AU2020444897A1 (en) 2020-04-30 2022-12-08 Synedgen, Inc. Compositions and methods of use thereof
EP4406542A1 (en) 2023-01-26 2024-07-31 BioKuris Treatment of gut inflammatory diseases
WO2026128424A1 (en) * 2024-12-10 2026-06-18 Immunophotonics, Inc Compositions of chitosan and modified chitosans

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4532134A (en) 1981-04-06 1985-07-30 Malette William Graham Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound
CA2181048C (en) * 1994-01-14 2003-05-06 Lee Shahinian, Jr. A method for sustained and extended corneal analgesia
US7214202B1 (en) 1997-07-28 2007-05-08 Kci Licensing, Inc. Therapeutic apparatus for treating ulcers
EP1061937A1 (en) 1998-03-10 2000-12-27 University Of Southern California Improved radiation therapy methods
PT1100344E (pt) 1998-07-30 2004-09-30 Vital Living Inc Novas composicoes liquidas contendo quitosana e metodos para a sua preparacao e utilizacao
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
PT1128809E (pt) * 1998-11-20 2005-04-29 Medidom Lab Formulacoes oftalmicas aquosas comprendendo quitosano
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
JP2003012702A (ja) 2001-04-24 2003-01-15 Sankyo Co Ltd 低分子キトサンの製造方法
US20060127873A1 (en) 2002-07-16 2006-06-15 Caroline Hoemann Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors
GB2393120A (en) 2002-09-18 2004-03-24 Johnson & Johnson Medical Ltd Compositions for wound treatment
GB0302741D0 (en) 2003-02-06 2003-03-12 Advanced Biopolymers As Use
GB0303085D0 (en) 2003-02-11 2003-03-19 Pfizer Ltd Model
EP1771138A4 (en) 2004-07-26 2009-08-19 Kci Licensing Inc METHOD FOR COVERING ANTIMICROBIAL AGENT SUBSTRATE AND PRODUCT THUS FORMED
CN1965650A (zh) 2005-11-14 2007-05-23 陈祖辉 多元金属离子螯合的甲壳素绿色抗菌剂
CA2848648C (en) * 2006-06-02 2017-10-10 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2009136291A2 (en) * 2008-05-09 2009-11-12 Regenics As Cellular extracts
WO2010021930A1 (en) 2008-08-16 2010-02-25 Synedgen, Inc. Prevention and treatment of mrsa infections with chitosan-derivatives
CA2732438A1 (en) 2008-08-29 2010-03-04 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
CA2743624C (en) 2008-11-12 2017-06-20 Synedgen, Inc. Chitosan derivatives to treat animals or optimize animal health
EP2387409A1 (en) 2008-11-12 2011-11-23 Synedgen, Inc. Chitosan derivatives alone or in combination for the treatment of mdr microbial infections
WO2010088565A1 (en) 2009-01-29 2010-08-05 Synedgen, Inc. Nucleic acid delivery using modified chitosans
AU2010259284A1 (en) 2009-06-10 2011-12-15 Exthera Ab Use of a composition for the treatment of mucositis
CA3004707C (en) 2009-09-02 2022-05-31 Synedgen Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
WO2011028968A1 (en) 2009-09-02 2011-03-10 Synedgen, Inc. Oral care methods and compositions utilizing chitosan-derivative compounds
ES2773017T3 (es) 2010-04-06 2020-07-09 Synedgen Inc Derivados de quitosano para el tratamiento de mucositis o ulceración
CA2840749A1 (en) 2011-07-01 2013-01-10 Synedgen, Inc. Methods and compositions of reducing and preventing bacterial growth and the formation of biofilm on a surface utilizing chitosan-derivative compounds
US8735571B2 (en) 2011-12-22 2014-05-27 Agenta Biotechnologies, Inc. Composition, preparation, and use of dense chitosan membrane materials
US20150031610A1 (en) 2012-03-05 2015-01-29 Synedgen, Inc. Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins
US10022393B2 (en) 2012-09-20 2018-07-17 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation, trauma or shock
CA2905404C (en) 2013-03-12 2021-07-20 Synedgen, Inc. Oral formulations of polyglucosamine derivatives in combination with a non-fermentable sugar
WO2014172040A1 (en) 2013-03-15 2014-10-23 Synedgen Inc. Compositions and methods of use for wound healing
AU2015314775A1 (en) 2014-09-11 2017-03-30 Synedgen, Inc. Compositions and methods of use thereof
WO2018202783A1 (en) 2017-05-03 2018-11-08 Croma-Pharma Gmbh Sterile aqueous ophthalmic solution containing n-(n-acetylcysteinyl)-chitosan for treating non-infectious corneal disorders
US11390408B2 (en) 2020-11-24 2022-07-19 Axon Llc System and method for applying tubular bands to containers utilizing angled band ejection

Also Published As

Publication number Publication date
JP6000397B2 (ja) 2016-09-28
US20170119810A1 (en) 2017-05-04
AU2011237682B2 (en) 2016-04-21
US20240197769A1 (en) 2024-06-20
US9439925B2 (en) 2016-09-13
EP2555760A1 (en) 2013-02-13
US20130210761A1 (en) 2013-08-15
ES2773017T3 (es) 2020-07-09
JP2016033164A (ja) 2016-03-10
US20250345355A1 (en) 2025-11-13
JP2015129189A (ja) 2015-07-16
JP2013523827A (ja) 2013-06-17
US11717532B2 (en) 2023-08-08
JP2017226706A (ja) 2017-12-28
EP2555760B1 (en) 2019-10-16
WO2011127144A1 (en) 2011-10-13
EP2555760A4 (en) 2013-08-21
CA2795520A1 (en) 2011-10-13
AU2011237682A1 (en) 2012-11-01
US20180200286A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
US20250345355A1 (en) Methods and compositions for treating wounds utilizing chitosan compounds
US20230321145A1 (en) Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces
US10471151B2 (en) Composition for use in treating and preventing inflammation related disorder
US10561677B2 (en) Anti-bacterial applications of poly-N-acetylglucosamine nanofibers
US20240350529A1 (en) Compositions and methods of use thereof
Gronkiewicz et al. Effects of topical hyaluronic acid on corneal wound healing in dogs: a pilot study
CA2883704A1 (en) Methods for treatment or prevention of damage resulting from radiation, trauma or shock
JP2016519667A (ja) 創傷治癒のための組成物および使用方法
AU2015269353B2 (en) Methods of treating chronic dry eye disease using C16:1n7 palmitoleate and derivatives thereof
Liu et al. Antibiotic delivery system for treating bacteria-induced anterior blepharitis
EP3570815B1 (en) Composition for ophthalmic use
CN105214071A (zh) 一种纤连蛋白类滴眼液及其制备方法
RU2473335C1 (ru) Способ консервативного лечения дакриостеноза
US20160193343A1 (en) Composition for use in treating and preventing inflammation related disorder
CN104622890B (zh) 一种术后防粘连产品及其制备方法和用途
PL237591B1 (pl) Nowe zastosowanie medyczne kwasu kynureninowego i jego soli w leczeniu spojówki i rogówki oka

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140409

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328